

WHAT IS CLAIMED IS:

1. A crystalline form of Compound A.
2. The crystalline form of claim 1, wherein the crystalline form is Compound A Form 2.
3. The crystalline form of claim 1, wherein the crystalline form is Compound A Form 4.
4. The crystalline form of claim 1, wherein the crystalline form is Compound A Form 9.
5. The crystalline form of claim 1, wherein the crystalline form is Compound A Form 11.
6. A solid state form of Compound A comprising two or more of the crystalline forms of claims 2-5.
7. The crystalline form of any one of claims 2-5, wherein the crystalline form is substantially free of the other solid state forms.
8. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a crystalline form of Compound A.
9. The pharmaceutical composition of claim 8, wherein the crystalline form of Compound A is Compound A Form 2.
10. The pharmaceutical composition of claim 8, wherein the crystalline form of Compound A is Compound A Form 4.
11. The pharmaceutical composition of claim 8, wherein the crystalline form of Compound A is Compound A Form 9.
12. The pharmaceutical composition of claim 8, wherein the crystalline form of Compound A is Compound A Form 11.
13. A pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier and/or diluent and a mixture of two or more crystalline forms of Compound A.

14. A method of treating a seizure disorder in a human, wherein the method comprises administering a therapeutically effective amount of a crystalline form of Compound A to the human in need thereof.
15. The method of claim 14, wherein the crystalline form of Compound A is Compound A Form 2.
16. The method of claim 14, wherein the crystalline form of Compound A is Compound A Form 4.
17. The method of claim 14, wherein the crystalline form of Compound A is Compound A Form 9.
18. The method of claim 14, wherein the crystalline form of Compound A is Compound A Form 11.
19. A method of treating a seizure disorder in a human, wherein the method comprises administering a therapeutically effective amount of a mixture of two or more crystalline forms of Compound A to the human in need thereof.
20. A method of preparing a crystalline form of Compound A from another crystalline form of Compound A.
21. A method of preparing a pharmaceutical composition comprising a pharmaceutical excipient and a crystalline form of Compound A, the method comprising combining the crystalline form of Compound A with the pharmaceutical excipient to form the pharmaceutical composition.
22. The method of any one of claims 14-19, wherein the crystalline form of Compound A is administered to the human from between 30 minutes before to 2 hours after eating a meal.
23. The method of claim 22, wherein the crystalline form of Compound A is administered during a meal or within 15 minutes after eating a meal.

24. Use of a crystalline form of Compound A in the manufacture of a medicament for treating a seizure disorder in a human in need thereof.
25. The use of claim 24, wherein the crystalline form of Compound A is Compound A Form 2.
26. The use of claim 24, wherein the crystalline form of Compound A is Compound A Form 4.
27. The use of claim 24, wherein the crystalline form of Compound A is Compound A Form 9.
28. The use of claim 24, wherein the crystalline form of Compound A is Compound A Form 11.
29. Use of a mixture of two or more crystalline forms of Compound A in the manufacture of a medicament for treating a seizure disorder in a human in need thereof.
30. The use of any one of claims 24-29, wherein the human is treated with the crystalline form of Compound A from between 30 minutes before to 2 hours after eating a meal.
31. The use of claim 30, wherein the human is treated with the crystalline form of Compound A during a meal or within 15 minutes after eating a meal.